Answers are grounded in this paper and cite their sources.
Analysis identifies new antifungal agents for treating invasive fungal infections, highlighting drug resistance challenges.
Introduction The prevalence of invasive fungal infections (IFI) is increasing globally, with approximately 6,500,000 cases of IFI per year and 3,800,000 deaths. Most IFI deaths are attributable to opportunistic mycoses, such as Aspergillus and Candida. However, changes in climate and travel are leading to rising rates of endemic mycoses. Compounding this burden is the rise of antifungal drug resistance, requiring the development of new agents.
No takes yet. Share an insight, caveat, or question.
Maves et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: